Literature DB >> 31823171

ASO Author Reflections: Systemic Immune-Inflammation Index (SII) as a Biomarker of Response to Neoadjuvant Therapy in Patients with Pancreatic Adenocarcinoma.

Pranav Murthy1, Brian A Boone2.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 31823171      PMCID： PMC7490754          DOI： 10.1245/s10434-019-08136-7

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN： 1068-9265            Impact factor:   5.344


× No keyword cloud information.
  7 in total

1.  Serum CA 19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma.

Authors:  Brian A Boone; Jennifer Steve; Mazen S Zenati; Melissa E Hogg; Aatur D Singhi; David L Bartlett; Amer H Zureikat; Nathan Bahary; Herbert J Zeh
Journal:  Ann Surg Oncol       Date:  2014-08-05       Impact factor: 5.344

2.  Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators.

Authors:  Matthew H G Katz; Jason B Fleming; Priya Bhosale; Gauri Varadhachary; Jeffrey E Lee; Robert Wolff; Huamin Wang; James Abbruzzese; Peter W T Pisters; Jean-Nicolas Vauthey; Chusilp Charnsangavej; Eric Tamm; Christopher H Crane; Aparna Balachandran
Journal:  Cancer       Date:  2012-05-17       Impact factor: 6.860

3.  A peaceful death orchestrates immune balance in a chaotic environment.

Authors:  Adam C Soloff; Michael T Lotze
Journal:  Proc Natl Acad Sci U S A       Date:  2019-10-25       Impact factor: 11.205

4.  Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer.

Authors:  Cristina R Ferrone; Giovanni Marchegiani; Theodore S Hong; David P Ryan; Vikram Deshpande; Erin I McDonnell; Francesco Sabbatino; Daniela Dias Santos; Jill N Allen; Lawrence S Blaszkowsky; Jeffrey W Clark; Jason E Faris; Lipika Goyal; Eunice L Kwak; Janet E Murphy; David T Ting; Jennifer Y Wo; Andrew X Zhu; Andrew L Warshaw; Keith D Lillemoe; Carlos Fernández-del Castillo
Journal:  Ann Surg       Date:  2015-01       Impact factor: 12.969

5.  The Systemic-immune-inflammation Index Independently Predicts Survival and Recurrence in Resectable Pancreatic Cancer and its Prognostic Value Depends on Bilirubin Levels: A Retrospective Multicenter Cohort Study.

Authors:  Mohammad Hosein Aziz; Kostandinos Sideras; Nasir Ahmad Aziz; Katya Mauff; Roel Haen; Daphne Roos; Lawlaw Saida; Mustafa Suker; Erwin van der Harst; Jan Sven Mieog; Bert A Bonsing; Yarne Klaver; Bas Groot Koerkamp; Casper H van Eijck
Journal:  Ann Surg       Date:  2019-07       Impact factor: 12.969

6.  Prognostic Value of the Systemic Immune-Inflammation Index (SII) After Neoadjuvant Therapy for Patients with Resected Pancreatic Cancer.

Authors:  Pranav Murthy; Mazen S Zenati; Amr I Al Abbas; Caroline J Rieser; Nathan Bahary; Michael T Lotze; Herbert J Zeh; Amer H Zureikat; Brian A Boone
Journal:  Ann Surg Oncol       Date:  2019-12-02       Impact factor: 5.344

7.  Systemic Immune-Inflammation Index (SII) Predicts Poor Survival in Pancreatic Cancer Patients Undergoing Resection.

Authors:  Gerd Jomrich; Elisabeth S Gruber; Daniel Winkler; Marlene Hollenstein; Michael Gnant; Klaus Sahora; Martin Schindl
Journal:  J Gastrointest Surg       Date:  2019-03-28       Impact factor: 3.452
  7 in total
  2 in total

1.  Pretreatment Systemic Immune-Inflammation Index Can Predict Response to Neoadjuvant Chemotherapy in Cervical Cancer at Stages IB2-IIB.

Authors:  Pingping Liu; Yinan Jiang; Xiaojing Zheng; Baoyue Pan; Huiling Xiang; Min Zheng
Journal:  Pathol Oncol Res       Date:  2022-04-27       Impact factor: 2.874

2.  High Systemic Immune Inflammation Index Is Associated With Low Skeletal Muscle Quantity in Resectable Pancreatic Ductal Adenocarcinoma.

Authors:  Mohammad Hosein Aziz; Jelle C van Dongen; Lawlaw Saida; Mustafa Suker; Jeroen L A van Vugt; Yordi van Putten; Kostandinos Sideras; Jesse V Groen; J Sven D Mieog; Claudia J Lucassen; Anneke Droop; Katya Mauff; Shirin Shahbazi Feshtali; Bas Groot Koerkamp; Dana A M Mustafa; Casper J van Eijck
Journal:  Front Oncol       Date:  2022-02-28       Impact factor: 6.244
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.